Zoya Gluzman-Poltorak

Zoya Gluzman-Poltorak has been working in the field of therapeutic development for over two decades. Zoya is currently the VP of Therapeutic Development at ASC Therapeutics. Prior to their current position, they were the Senior Director of Development and Head of Immuno-Oncology at Neumedicines Inc.

Gluzman-Poltorak has experience with a wide range of therapeutic areas, including hematology/oncology, solid tumors, and surgical wound immunotherapy. Zoya has also worked extensively with government contracts and grants from organizations such as the Department of Defense, National Institutes of Health, and Biomedical Advanced Research and Development Authority.

Gluzman-Poltorak has a strong track record of successful project management, with experience overseeing both pre-clinical and clinical development stages. Zoya has also authored nine peer-reviewed articles.

Zoya Gluzman-Poltorak has an MBA from Technion - Israel Institute of Technology, a PhD in Angiogenesis, Tumorogenesis, Molecular&Cell Biology, Genetic Engineering from Technion - Israel Institute of Technology, an MSc in Cellular and Molecular Biology, Genetic Engineering from Technion - Israel Institute of Technology, and a BSc in Biology/Biological Sciences, General from Technion - Israel Institute of Technology. Zoya also has a degree in Medicine from Vinnitsa National Medical University.

Their manager is Ruhong Jiang, Co-Founder, President & CEO. Zoya Gluzman-Poltorak works with Weicheng Wu - VP, Global Regulatory Affairs, Gary Potter - SVP, Global Operations, and Steve Zhang - VP, Gene & Cell Therapy.